NCT04869137 2026-04-08
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
44 trialsNCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01319565 2025-12-19
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03714828 2024-10-09
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
University of Arizona
Phase 2 Completed
NCT04337931 2024-02-13
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
Phase 2 Terminated
NCT02036476 2023-05-09
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02083354 2022-02-01
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis
Phase 2 Completed
NCT01835626 2021-05-03
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT02347813 2020-06-23
Preventing Squamous Cell Skin Cancer
University of Rochester
Phase 2 Completed
NCT02705352 2020-03-09
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Massachusetts Eye and Ear Infirmary
Phase 2 Completed
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01264081 2019-11-13
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00254397 2019-10-16
Melanoma Vaccine With Peptides and Leuprolide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02302339 2019-09-06
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Celldex Therapeutics
Phase 2 Terminated
NCT00126555 2019-08-30
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT02303041 2019-01-29
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT01108094 2018-11-13
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Stanford University
Phase 2 Completed
NCT00804908 2018-06-06
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
AbbVie
Phase 2 Completed
NCT01823679 2018-04-12
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Stanford University
Phase 2 Terminated
NCT01009515 2017-10-18
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT02111863 2017-09-19
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01271907 2017-08-01
Drosophila-generated CTL
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01059305 2017-04-04
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00601640 2017-03-23
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
University of Arizona
Phase 2 Completed
NCT01468818 2016-06-27
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00588341 2016-02-01
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01474551 2015-11-18
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00610311 2015-10-28
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00612222 2015-10-28
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00923195 2015-10-28
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00665470 2015-10-19
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01495572 2015-10-15
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01118091 2015-10-08
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00563290 2015-06-18
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00885534 2015-05-06
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00054691 2015-03-13
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00513604 2013-06-03
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00509496 2013-01-15
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00509288 2012-12-28
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00094107 2012-06-26
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Pfizer
Phase 2 Completed